Merck Announces Third-Quarter 2013 Dividend
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today
announced that the Board of Directors has declared a quarterly dividend
of $0.43 per share on the company’s common stock for the third quarter
of 2013. Payment will be made on July 8, 2013, to stockholders of record
at the close of business on June 17, 2013.
About Merck
Language:
English
Contac...
Source: Merck.com - Corporate News - May 28, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Latest News Source Type: news
Merck Announces $5 Billion Accelerated Share Repurchase
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that it has entered into an accelerated share repurchase
agreement (ASR) with Goldman, Sachs & Co. to repurchase $5 billion of
Merck’s common stock. Proceeds from the company’s recently
concluded debt offering were used to execute the ASR, which is part
of Merck’s previously announced $15
billion share repurchase program.
Language:&nb...
Source: Merck.com - Corporate News - May 21, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Latest News Source Type: news
Merck to Present at the UBS Global Healthcare Conference
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that Peter N. Kellogg, executive vice president and
chief financial officer, Merck, is scheduled to present at the UBS
Global Healthcare Conference in New York City on May 20, 2013 at 10:30
a.m. EDT. Investors, analysts, members of the media and the general
public are invited to join a live webcast of the presentation at: http://www.merck.com/investors/events-an...
Source: Merck.com - Corporate News - May 17, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Latest News Source Type: news
Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently
Dateline City:
NEW YORK
A New 5-year Guarantee Has the Potential to Unlock Immense Private Sector Financing, Accelerating Efforts to Achieve MDGs
NEW YORK--(BUSINESS WIRE)--Today, leading global health and development experts from the public and
private sectors are joining forces at the 2013 GBCHealth Conference to
announce a new partnership that will leverage private sector funding to
speed up delivery and access to life-saving health supplies, such as
contr...
Source: Merck.com - Corporate News - May 17, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
Merck Prices $ 6.5 Billion Debt Offering
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. priced today a $6.5 billion public offering of senior
unsecured notes. The notes include:
$1,000 million of 0.70% notes due May 2016$500 million of floating
rate notes due May 2016$1,000 million of 1.30% notes due May 2018$1,000
million of floating rate notes due May 2018$1,750 million of 2.80%
notes due May 2023$1,250 million of 4.15% notes due May 2043
Language:
...
Source: Merck.com - Corporate News - May 15, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Latest News Source Type: news
Merck for Mothers Launches Initiative in India to Reduce the Number of Women Dying During Pregnancy and Childbirth
Dateline City:
DELHI, INDIA
$10 Million Commitment to Improve Access to Maternal Health Services in Areas with High Rates of Maternal Deaths
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Merck for Mothers has launched its global initiative for helping reduce maternal mortality in India. It is partnering with three leading non-governmental organizations to improve the quality of healthcare that pregnant women in India receive through the private sector.
La...
Source: Merck.com - Corporate News - May 14, 2013 Category: Pharmaceuticals Authors: Maria.tortoreto at merck.com Tags: HLFPPT India K. G. Ananthakrishnan M$M Mamta Sharma Merck Merck for Mothers Millennium Development Goal MRK MSD MSD for Mothers Naveen Rao Pathfinder WRA Corporate News Corporate Responsibility News Latest News Source Type: news
Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that Frank Clyburn, president, Primary Care and Women's
Health, Merck, is scheduled to present at the Bank of America/Merrill
Lynch 2013 Healthcare Conference in Las Vegas, Nevada, on May 15, 2013
at 9:20 a.m. PDT. Investors, analysts, members of the media and the
general public are invited to join a live webcast of the presentation
at: http://www.merck.c...
Source: Merck.com - Corporate News - May 14, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Latest News Source Type: news
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Merck’s HPV Vaccine, Available to Developing Countries through UNICEF Tender
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the company has been awarded a significant portion
of the UNICEF human papillomavirus (HPV) vaccine tender, and will
provide sustained supply of GARDASIL® [Human Papillomavirus
Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] to
GAVI-eligible countries. This agreement follows the GAVI Alliance’s
earlier announcement that HPV vaccines w...
Source: Merck.com - Corporate News - May 9, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Prescription Medicine News Vaccine News Corporate News Latest News Source Type: news
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Biologics License Application (BLA) for its
investigational ragweed pollen (Ambrosia artemisiifolia)
sublingual allergy immunotherapy tablet has been accepted for review by
the U.S. Food and Drug Administration (FDA). On March 27, Merck
announced that the FDA had also accepted the BLA for its investigational Timothy
grass pollen (Phleum pratense)...
Source: Merck.com - Corporate News - May 8, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck and Celebrity Chef Art Smith “Cook Up a Recipe” for Better Type 2 Diabetes Management
Dateline City:
WHITEHOUSE STATION, N.J.
Taking Diabetes to Heart Program Helps People Make Small but Important Lifestyle Changes
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced its partnership with celebrity chef Art Smith onTaking Diabetes to Heart, an educational program to help people living with type 2 diabetes better manage the disease.
Language:
English
read more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - May 7, 2013 Category: Pharmaceuticals Authors: Maria.tortoreto at merck.com Tags: Consumer Care News Corporate News Latest News Source Type: news
FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
Dateline City:
WHITEHOUSE STATION, N.J.
LIPTRUZET Approved for Patients with Primary or Mixed Hyperlipidemia, as an Adjunct to Diet When Diet Alone Is Not Enough
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET™(ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet w...
Source: Merck.com - Corporate News - May 3, 2013 Category: Pharmaceuticals Authors: Maria.tortoreto at merck.com Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Announces First-Quarter 2013 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
2013 First-Quarter Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.52
Worldwide Sales were $10.7 Billion, a Decrease of 9 Percent Primarily as a Result of Patent Expiries, and Including a 2 Percent Unfavorable Impact from Foreign Exchange
Growth in Vaccines, Immunology, HIV, Animal Health and Consumer Care Products
Received Breakthrough Therapy Designation for Lambrolizumab, an...
Source: Merck.com - Corporate News - May 1, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Source Type: news
Merck Announces New $15 Billion Share Repurchase Program
Dateline City:
WHITEHOUSE STATION, N.J.
Company’s expanded program now totals $16.1 billion
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that its board of directors has authorized additional
purchases of up to $15 billion of Merck’s common stock for its treasury.
The company expects to repurchase approximately $7.5 billion of common
stock over the next 12 months, financed through...
Source: Merck.com - Corporate News - May 1, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Source Type: news
Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today said a
jury found in its favor in the Glynn v. Merck case in the U.S.
District Court for the District of New Jersey. In the case, the
plaintiff claimed she used FOSAMAX and subsequently suffered an atypical
femur fracture.
Language:
English
Contact HTML:
...
Source: Merck.com - Corporate News - April 29, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Source Type: news
Merck Opens New Manufacturing Facility in Hangzhou, China
Dateline City:
WHITEHOUSE STATION, N.J.
New facility to deliver innovative, high-quality Merck medicines to Asia
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the opening of its new pharmaceutical manufacturing facility in Hangzhou, China. The facility, located in the Hangzhou Economic and Technology Area (HEDA), will package Merck medicines for China and the Asia Pacific region and will become a critical part of Merck’s global supply chain.
“This new facili...
Source: Merck.com - Corporate News - April 16, 2013 Category: Pharmaceuticals Authors: Maria.tortoreto at merck.com Tags: Corporate News Source Type: news
